back to the overview


Press Release; Berlin, October 18, 2006


MOLOGEN AG - Basic patent legally valid in Europe


The Berlin based Biotech company MOLOGEN announced today, that the basic patent for MIDGE®-TH1 technology has become legally binding in Europe.

The patent is valid until 2020. After the patent was granted in December 2005, competitors were allowed to file formal objection within a period of nine month. This period has now expired, and an effective legal protection of the patent in Europe has come into force.

Besides MIDGE® and dSLIM®, MIDGE®-TH1 is one fundamental core technology for product development of MOLOGEN. MIDGE-TH1 facilitates the design of highly specific and most efficient DNA vaccines in a way that the so called TH1 pathway of the immune system is triggered to overcome infections. This TH1 pathway is required to fight pathogens which replicate within the cell.



MOLOGEN AG is a listed biopharmaceutical company with headquarters in Berlin (Frankfurt Stock Exchange, Regulated Market, ISIN DE0006637200). On the basis of patented technologies (MIDGE and dSLIM), MOLOGEN develops DNA-based vaccines and therapeutic agents for the prevention and treatment of a wide range of serious illnesses.


Disclaimer concerning prognoses

Certain statements in this communication contain formulations or terms referring to the future or future developments, as well as negations of such formulations or terms, or similar terminology. These are described as forward-looking statements. In addition, all information in this communication regarding planned or future results of business segments, financial classification numbers, developments of the financial situation, or other financial or statistical data contains such forward-looking statements. The company cautions prospective investors not to rely on such forward-looking statements as certain prognoses of actual future events and developments. The company is neither responsible nor liable for these forward-looking statements. It is not responsible for updating such information, which only represents the state of affairs on the day of publication.


 back to the overview


Investor & Public Relations

  Joerg Petrass

Research & Development

  Dr. Matthias Schroff

Business Development

  Arlett Killat


To subscribe to our Newsletter please

 click here


To view our Reports

  click here